Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from NATCO Pharma Limited ( (IN:NATCOPHARM) ).
Natco Pharma Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. This certificate confirms that securities received for dematerialization have been processed correctly, with updates made to the depositories’ records, ensuring compliance with regulatory requirements. This announcement underscores Natco Pharma’s commitment to maintaining regulatory compliance and transparency in its operations, which is crucial for its stakeholders and market reputation.
More about NATCO Pharma Limited
Natco Pharma Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of generic drugs and specialty pharmaceuticals. The company is known for its strong presence in the Indian market and its efforts to expand internationally.
Average Trading Volume: 61,410
Technical Sentiment Signal: Sell
Current Market Cap: 145.3B INR
Learn more about NATCOPHARM stock on TipRanks’ Stock Analysis page.